This diagnostic trial seeks to help patients with smoldering multiple myeloma (SMM) take control of monitoring their disease. Roughly 50% of patients with SMM will progress to active disease within 5 years from diagnosis, 7% of whom will progress to light chain amyloidosis (AL). AL is a disease where plasma cells produce light chains that misfold and can accumulate throughout the body and cause organ dysfunction. AL is frequently overlooked as a diagnosis, which allows more time for harmful proteins to build up in different organs, making the disease much harder to treat. One of the most effective ways you can take control of your disease is taking active measures to catch any signs of progression as early as possible.
SparkCures ID | 811 |
---|---|
Enrollment | 200 Patients |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers